FTSE starts new week in slightly stronger mode
Rio Tinto shares were hit after the company decided to abandon plans to IPO its Canadian iron ore operations after six years of trying unsuccessfully.
Share this:
Rio Tinto shares were hit after the company decided to abandon plans to IPO its Canadian iron ore operations after six years of trying unsuccessfully. The decline was fairly moderate, down 0.5%, far behind some of today’s bigger fallers such as Whitbread and AstraZeneca.
The GlaxoSmithKline vs AstraZeneca race to capture the market for ovarian cancer drugs put Glaxo in the lead this morning with the release of the data for its latest drug showing an improvement on AstraZeneca’s most recent product. The two companies are almost neck-a-neck in developing drugs for this specific type of cancer and the release helped Glaxo gain 1.6% while AstraZeneca slipped 1.8%.
UK GDP, Conservative conference to steer sterling trade
Pound crosses will be in focus in the forex market later this morning after the UK reports its final numbers for second quarter GDP. Brexit uncertainty is expected to have continued to erode GDP growth between April and June compared with the first quarter but year on year GDP should still be showing some improvement.
Otherwise the pound is a touch firmer as the Conservative Party starts its conference in Manchester which is likely to see a replay of the heated debates at Labour’s party conference witnessed last week as the party remains deeply divided over what course to take next.
Brent crude is trading just a whisker above $60 after Chinese PMI data showed that the country’s manufacturing is still teetering on the verge of contraction.
The GlaxoSmithKline vs AstraZeneca race to capture the market for ovarian cancer drugs put Glaxo in the lead this morning with the release of the data for its latest drug showing an improvement on AstraZeneca’s most recent product. The two companies are almost neck-a-neck in developing drugs for this specific type of cancer and the release helped Glaxo gain 1.6% while AstraZeneca slipped 1.8%.
UK GDP, Conservative conference to steer sterling trade
Pound crosses will be in focus in the forex market later this morning after the UK reports its final numbers for second quarter GDP. Brexit uncertainty is expected to have continued to erode GDP growth between April and June compared with the first quarter but year on year GDP should still be showing some improvement.
Otherwise the pound is a touch firmer as the Conservative Party starts its conference in Manchester which is likely to see a replay of the heated debates at Labour’s party conference witnessed last week as the party remains deeply divided over what course to take next.
Brent crude is trading just a whisker above $60 after Chinese PMI data showed that the country’s manufacturing is still teetering on the verge of contraction.
Rio Tinto shares were hit after the company decided to abandon plans to IPO its Canadian iron ore operations after six years of trying unsuccessfully. The decline was fairly moderate, down 0.5%, far behind some of today’s bigger fallers such as Whitbread and AstraZeneca.
The GlaxoSmithKline vs AstraZeneca race to capture the market for ovarian cancer drugs put Glaxo in the lead this morning with the release of the data for its latest drug showing an improvement on AstraZeneca’s most recent product. The two companies are almost neck-a-neck in developing drugs for this specific type of cancer and the release helped Glaxo gain 1.6% while AstraZeneca slipped 1.8%.
UK GDP, Conservative conference to steer sterling trade
Pound crosses will be in focus in the forex market later this morning after the UK reports its final numbers for second quarter GDP. Brexit uncertainty is expected to have continued to erode GDP growth between April and June compared with the first quarter but year on year GDP should still be showing some improvement.
Otherwise the pound is a touch firmer as the Conservative Party starts its conference in Manchester which is likely to see a replay of the heated debates at Labour’s party conference witnessed last week as the party remains deeply divided over what course to take next.
Brent crude is trading just a whisker above $60 after Chinese PMI data showed that the country’s manufacturing is still teetering on the verge of contraction.
The GlaxoSmithKline vs AstraZeneca race to capture the market for ovarian cancer drugs put Glaxo in the lead this morning with the release of the data for its latest drug showing an improvement on AstraZeneca’s most recent product. The two companies are almost neck-a-neck in developing drugs for this specific type of cancer and the release helped Glaxo gain 1.6% while AstraZeneca slipped 1.8%.
UK GDP, Conservative conference to steer sterling trade
Pound crosses will be in focus in the forex market later this morning after the UK reports its final numbers for second quarter GDP. Brexit uncertainty is expected to have continued to erode GDP growth between April and June compared with the first quarter but year on year GDP should still be showing some improvement.
Otherwise the pound is a touch firmer as the Conservative Party starts its conference in Manchester which is likely to see a replay of the heated debates at Labour’s party conference witnessed last week as the party remains deeply divided over what course to take next.
Brent crude is trading just a whisker above $60 after Chinese PMI data showed that the country’s manufacturing is still teetering on the verge of contraction.
Open an account in minutes
Experience award-winning platforms with fast and secure execution, and enjoy tight spreads from 0.5 pts on FX and 0.3 pts on indices.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.
Related articles
EUR/USD Q4 2026 Outlook: Euro at a Crossroads as Fed, ECB Tighten 9 25 2026
EUR/USD enters Q4 at a pivotal inflection point as competing Fed-ECB policy paths and persistent inflation risks collide with major technical support.
AUD/USD Q4 Outlook: RBA and Fed Hikes Set the Tone
AUD/USD enters Q4 with RBA and Fed hikes in focus as sticky inflation, rising unemployment and US dollar strength shape the Australian dollar.
USD/JPY Q4 2026 Outlook: Hawkish Fed Pricing Clashes With Intervention Risk
The year-end tug-of-war is clear: hawkish Fed pricing supports USD/JPY, while intervention risk limits the upside.
This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.
StoneX Financial Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the StoneX group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), StoneX Financial Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact StoneX Financial Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.
In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither StoneX Financial Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.
StoneX Financial Pte. Ltd. is not under any obligation to update this report.
Trading CFDs carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit www.forex.com/en-sg/terms-and-policies for the complete Risk Disclosure Statement.